Northwest Biotherapeutics (NWBO) Liabilities and Shareholders Equity (2010 - 2026)

Northwest Biotherapeutics' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $80.1 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 191.04% year-over-year to $80.1 million in Q1 2026; TTM through Mar 2026 was $221.5 million, a 98.16% increase from a year earlier, with the FY2025 full-year figure at $81.3 million, up 204.14% from the prior year.
• Liabilities and Shareholders Equity slipped to $80.1 million in Q1 2026 per NWBO's latest filing, from $81.3 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $81.3 million in Q4 2025 and bottomed at $26.7 million in Q4 2024.
• The 5-year median for Liabilities and Shareholders Equity is $29.5 million (2025), against an average of $35.5 million.
• Across the five-year window, Liabilities and Shareholders Equity declined 22.0% in 2022 and surged 204.14% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $31.3 million in 2022, then fell by 11.04% to $27.9 million in 2023, then slipped by 4.08% to $26.7 million in 2024, then jumped by 204.14% to $81.3 million in 2025, then dropped by 1.52% to $80.1 million in 2026.
• Per Business Quant, the three latest NWBO Liabilities and Shareholders Equity figures stand at $80.1 million (Q1 2026), $81.3 million (Q4 2025), and $30.6 million (Q3 2025).